RTTNews | Jul 21, 2021 10:05AM EDT

10:05 Wednesday, July 21, 2021 (RTTNews.com) - Shares of Lexaria Bioscience Corp. (LEXX, LEXXW) are gaining over 45% on Wednesday morning after the company announced that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results.

LEXX is currently trading at $9.61, up $3.02 or 45.83%, on the Nasdaq. On the Nasdaq GS market, Lexaria's stock is trading at $4.02, up $1.58 or 64.75%.

The study demonstrates that DehydraTECHTM enabled colchicine, the latest of several drugs Lexaria has successfully tested with known SARS-CoV-2 antiviral properties, benefited from our proprietary formulation and processing, resulting in increased delivery.

Colchicine is an approved therapeutic with anti-inflammatory effects that is principally used to treat gout and conditions such as cardiac inflammation, and also has potent effects in mitigating the cytokine storm associated with SARS-CoV-2/COVID-19.

Read the original article on RTTNews ( https://www.rttnews.com/3210690/lexaria-bioscience-surges-45-on-positive-results-from-viral-a20-3.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved